4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
Meet Veristat in Boston at DTRA
With nearly 30 years of experience in clinical trial planning and execution for complex cancer therapies, Veristat is equipped to support any development program.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
As a versatile scientific CRO and consultancy, we provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel cancer therapies. In the past five years, Veristat has supported more than 300 oncology studies and we have worked on more than 30 US and European regulatory marketing applications for cancer treatments.
Schedule A Meeting
If you would like to meet with a member of our team, please contact us through the form to arrange a meeting.
We are…Bold. Scientific. Versatile. Veristat.
Conference Details
Website: https://www.dtra.org/dtra-2023-annual-meeting
Schedule A Meeting
Veristat team members Cindy Hendershot, Chief Strategy Officer, and Erin Gaffney, Senior Business Development Director, will be at the venue, ready to listen to your needs and share Veristat’s expertise.
Meet with us at DTRA 2023 by filling out the form below.
10 min read
Monthly FDA Guidance and Regulatory News Review - May 2026
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...